Moneycontrol PRO

Buy Strides Pharma; target of Rs 930: Motilal Oswal

Motilal Oswal is bullish on Strides Pharma recommended buy rating on the stock with a target price of Rs 930 in its research report dated May 28, 2021.

June 10, 2021 / 11:33 AM IST
  • bselive
  • nselive
Todays L/H

Motilal Oswal's research report on Strides Pharma

STR’s 4QFY21 operational performance was marginally below our estimate. The robust performance in the US/Institutional segment within emerging markets was offset by subdued sales in other regulated markets on account of COVID-19. In addition to commercial manufacturing of the Sputnik vaccine by Oct’21, STR is building a basket of COVID-related medicines. The ANDA filing momentum is expected to pick-up in FY22, providing growth visibility in the US market.


We cut our FY22E/FY23E earnings estimate by 6% each to account for increased opex associated with logistics and increased price erosion in select products. We value STR on a 12-month forward SoTP basis – EV/EBITDA of 12x/7x/6x for the Regulated/Emerging Markets/Institutional segment – to arrive at our TP of INR930/share. Maintain Buy.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: May 31, 2021 12:36 pm

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark